Cargando…
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Though the pathophysiology of clinical obesity is undoubtedly multifaceted, several lines of clinical evidence implicate an important functional role for glucagon-like peptide 1 (GLP-1) signalling. Clinical studies assessing GLP-1 responses in normal weight and obese subjects suggest that weight gai...
Autores principales: | Anandhakrishnan, Ananthi, Korbonits, Márta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155232/ https://www.ncbi.nlm.nih.gov/pubmed/28031776 http://dx.doi.org/10.4239/wjd.v7.i20.572 |
Ejemplares similares
-
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018) -
Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities
por: Mossello, Enrico, et al.
Publicado: (2011) -
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
por: Yazıcı, Dilek, et al.
Publicado: (2022) -
The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021) -
Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)